B-lymphocyte Depletion Ameliorates Sjögren's Syndrome in Id3 Knockout Mice

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2007 May 3

PMID 17472721

Citations 41

Authors

Ikuko Hayakawa

Thomas F Tedder

Yuan Zhuang

Affiliations

Soon will be listed here.

Abstract

Sjögren's syndrome is an autoimmune disease in which immune cells chronically attack the lachrymal and salivary glands. The Id3 knockout mouse is a newly established animal model for primary Sjögren's syndrome. To address the role of B cells in Sjögren's syndrome and autoimmune disease, we studied the effect of CD20 monoclonal antibody treatment on the disease in Id3 knockout mice. Antibody treatment at 2-month intervals led to efficient and sustained B-cell depletion in Id3 knockout mice. A significant improvement of histopathology was observed accompanied by the recovery of saliva secretory function after CD20 antibody treatment. We further show that serum immunoglobulin G3, which is abnormally high in untreated Id3 knockout mice, was reduced after CD20 antibody treatment. This study establishes a new animal model for immunotherapy of Sjögren's symptoms and suggests a possible link between immunoglobulin G3 and disease pathology in Id3 knockout mice.

Citing Articles

The impact of alternate-day fasting on the salivary gland stem cell compartments in non-obese diabetic mice with newly established Sjögren's syndrome.

Li D, Onodera S, Yu Q, Zhou J Biochim Biophys Acta Mol Cell Res. 2024; 1871(7):119817.

PMID: 39159683 PMC: 11368138. DOI: 10.1016/j.bbamcr.2024.119817.

A Copernican revolution of multigenic analysis: A retrospective study on clinical exome sequencing in unclear genetic disorders.

Chetta M, Tarsitano M, Rivieccio M, Oro M, Cammarota A, De Marco M Comput Struct Biotechnol J. 2024; 23:2615-2622.

PMID: 39006921 PMC: 11245952. DOI: 10.1016/j.csbj.2024.06.011.

Alternate-Day Fasting Ameliorates Newly Established Sjögren's Syndrome-like Sialadenitis in Non-Obese Diabetic Mice.

Li D, Onodera S, Deng S, Alnujaydi B, Yu Q, Zhou J Int J Mol Sci. 2022; 23(22).

PMID: 36430269 PMC: 9695328. DOI: 10.3390/ijms232213791.

Involvement of B cells in the development of systemic sclerosis.

Yoshizaki A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Sato S Front Immunol. 2022; 13:938785.

PMID: 35967355 PMC: 9365989. DOI: 10.3389/fimmu.2022.938785.

Transgenic dry eye mouse models: powerful tools to study dry eye disease.

Qin D, Wang L, Deng Y Int J Ophthalmol. 2022; 15(4):635-645.

PMID: 35450189 PMC: 8995740. DOI: 10.18240/ijo.2022.04.18.

References

Voulgarelis M, Dafni U, Isenberg D, Moutsopoulos H . Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum. 1999; 42(8):1765-72. DOI: 10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V. View

Greenspan N, Cooper L . Cooperative binding by mouse IgG3 antibodies: implications for functional affinity, effector function, and isotype restriction. Springer Semin Immunopathol. 1993; 15(2-3):275-91. DOI: 10.1007/BF00201107. View

Fox R, Tornwall J, Michelson P . Current issues in the diagnosis and treatment of Sjögren's syndrome. Curr Opin Rheumatol. 1999; 11(5):364-71. DOI: 10.1097/00002281-199909000-00007. View

Hamaguchi Y, Uchida J, Cain D, Venturi G, Poe J, Haas K . The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. 2005; 174(7):4389-99. DOI: 10.4049/jimmunol.174.7.4389. View

Kovacs L, Marczinovits I, Gyorgy A, Toth G, Dorgai L, Pal J . Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome. Rheumatology (Oxford). 2005; 44(8):1021-5. DOI: 10.1093/rheumatology/keh672. View

Fox R . Sjögren's syndrome. Lancet. 2005; 366(9482):321-31. DOI: 10.1016/S0140-6736(05)66990-5. View

Pijpe J, van Imhoff G, Spijkervet F, Roodenburg J, Wolbink G, Mansour K . Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 2005; 52(9):2740-50. DOI: 10.1002/art.21260. View

Eisenberg R . Update on rituximab. Ann Rheum Dis. 2005; 64 Suppl 4:iv55-7. PMC: 1766904. DOI: 10.1136/ard.2005.042648. View

Zintzaras E, Voulgarelis M, Moutsopoulos H . The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005; 165(20):2337-44. DOI: 10.1001/archinte.165.20.2337. View

10.

Tedder T, Engel P . CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994; 15(9):450-4. DOI: 10.1016/0167-5699(94)90276-3. View

11.

Touma Z, Sayad J, Arayssi T . Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol. 2006; 35(4):323-5. DOI: 10.1080/03009740500484056. View

12.

Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B . Successful treatment of a patient with primary Sjögren's syndrome with Rituximab. Clin Rheumatol. 2005; 25(6):891-4. DOI: 10.1007/s10067-005-0086-0. View

13.

Willeke P, Gaubitz M, Schotte H, Becker H, Mickholz E, Domschke W . Clinical and immunological characteristics of patients with Sjögren's syndrome in relation to alpha-fodrin antibodies. Rheumatology (Oxford). 2006; 46(3):479-83. DOI: 10.1093/rheumatology/kel270. View

14.

Engel P, Zhou L, Ord D, Sato S, Koller B, Tedder T . Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995; 3(1):39-50. DOI: 10.1016/1074-7613(95)90157-4. View

15.

Kee B, Quong M, Murre C . E2A proteins: essential regulators at multiple stages of B-cell development. Immunol Rev. 2000; 175:138-49. View

16.

Edwards J, Cambridge G . Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001; 40(2):205-11. DOI: 10.1093/rheumatology/40.2.205. View

17.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H, Alexander E, Carsons S . Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61(6):554-8. PMC: 1754137. DOI: 10.1136/ard.61.6.554. View

18.

Jonsson R, Moen K, Vestrheim D, Szodoray P . Current issues in Sjögren's syndrome. Oral Dis. 2002; 8(3):130-40. DOI: 10.1034/j.1601-0825.2002.02846.x. View

19.

Silverman G, Weisman S . Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003; 48(6):1484-92. DOI: 10.1002/art.10947. View

20.

Uchida J, Hamaguchi Y, Oliver J, Ravetch J, Poe J, Haas K . The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004; 199(12):1659-69. PMC: 2212805. DOI: 10.1084/jem.20040119. View